Abstract
Prevalence and impact of occult HBV infection in HIV positive patients is controversial. The aims of this study were to determine the prevalence of occult HBV infection and its impact on histological and virological parameters. 52 HIV/HCV (but HBsAg-negative) co-infected patients, 29 HBsAg and anti-HCV negative chronic hepatitis, and 20 HBsAg positive chronic hepatitis controls were studied. DNA was extracted from frozen biopsies and amplified with primers for S, C and X regions, and for (ccc) HBV-DNA. Sera were tested for HBV-DNA with two quantitative assays (Cobas Amplicor HBV Monitor, and the real-time COBAS (r) Taqman HBV Test, Roche Diagnostics, UK). Occult HBV infection was detected in 7 (13.4%) liver biopsies of the study group, and in none case of the non viral chronic hepatitis group (p=0.04). All serum samples were HBV-DNA negative with Cobas Amplicor HBV monitor assay, while 3 cases were found positive with real time PCR. Statistical analysis didnt show any impact of occult HBV infection on liver histology, CD4+ cells count, HIV and HCV load, and ALT levels. Occult B infection is relatively frequent in HIV/HCV co-infected patients, and is underestimated by common HBV-DNA serological assays. However, it doesnt seem to exert a relevant impact.
Keywords: Occult HBV, HIV/HCV-co-infection, chronic hepatitis, HBV-DNA
Current HIV Research
Title: Impact of Occult HBV Infection in HIV/HCV Co-Infected Patients: HBVDNA Detection in Liver Specimens and in Serum Samples
Volume: 6 Issue: 2
Author(s): Paolo Fabris, Maria R. Biasin, Maria T. Giordani, Laura Berardo, Vania Menini, Antonio Carlotto, Maria G. Miotti, Vinicio Manfrin, Vincenzo Baldo, Gaia Nebbia and Domenico Infantolino
Affiliation:
Keywords: Occult HBV, HIV/HCV-co-infection, chronic hepatitis, HBV-DNA
Abstract: Prevalence and impact of occult HBV infection in HIV positive patients is controversial. The aims of this study were to determine the prevalence of occult HBV infection and its impact on histological and virological parameters. 52 HIV/HCV (but HBsAg-negative) co-infected patients, 29 HBsAg and anti-HCV negative chronic hepatitis, and 20 HBsAg positive chronic hepatitis controls were studied. DNA was extracted from frozen biopsies and amplified with primers for S, C and X regions, and for (ccc) HBV-DNA. Sera were tested for HBV-DNA with two quantitative assays (Cobas Amplicor HBV Monitor, and the real-time COBAS (r) Taqman HBV Test, Roche Diagnostics, UK). Occult HBV infection was detected in 7 (13.4%) liver biopsies of the study group, and in none case of the non viral chronic hepatitis group (p=0.04). All serum samples were HBV-DNA negative with Cobas Amplicor HBV monitor assay, while 3 cases were found positive with real time PCR. Statistical analysis didnt show any impact of occult HBV infection on liver histology, CD4+ cells count, HIV and HCV load, and ALT levels. Occult B infection is relatively frequent in HIV/HCV co-infected patients, and is underestimated by common HBV-DNA serological assays. However, it doesnt seem to exert a relevant impact.
Export Options
About this article
Cite this article as:
Fabris Paolo, Biasin R. Maria, Giordani T. Maria, Berardo Laura, Menini Vania, Carlotto Antonio, Miotti G. Maria, Manfrin Vinicio, Baldo Vincenzo, Nebbia Gaia and Infantolino Domenico, Impact of Occult HBV Infection in HIV/HCV Co-Infected Patients: HBVDNA Detection in Liver Specimens and in Serum Samples, Current HIV Research 2008; 6 (2) . https://dx.doi.org/10.2174/157016208783885029
DOI https://dx.doi.org/10.2174/157016208783885029 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metastatic Breast Cancer, Organotropism and Therapeutics: A Review
Current Cancer Drug Targets Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Towards a Gene Therapy Clinical Trial for Epidermolysis Bullosa
Reviews on Recent Clinical Trials Proteomic Classification of Breast Cancer
Current Drug Targets Application of Artificial Neural Networks for the Prediction of Antitumor Activity of a Series of Acridinone Derivatives
Medicinal Chemistry Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology The Role of DNA-Microarray in Translational Cancer Research
Current Pharmacogenomics Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
Current Radiopharmaceuticals Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Myokines in Myogenesis and Health
Recent Patents on Biotechnology Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Cardiovascular & Hematological Agents in Medicinal Chemistry Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy The Role of Signaling Pathway in the Biological Cause of Rheumatoid Arthritis
Current Drug Research Reviews Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Pharmaceutical Nanotechnology Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology